Brian Druker
President, Knight Cancer Group · Oregon Health & Science University
Credentials: · · · ·
History
- Present
Oncology · Oregon Health & Science University
- Present
Leukemia Research Department · Oregon Health & Science University
- Present
OHSU Knight Cancer Institute Center · Oregon Health & Science University
- 1982–1985
- 1981–1982
- 1977–1981
- 1973–1977
University of California, San
Research
New England Journal of Medicine · 2001 · First of 11 authors · Corresponding · 4,052 citations
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
New England Journal of Medicine · 2002 · 3,431 citations
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Nature Medicine · 1996 · First of 8 authors · 2,886 citations
108 papers
- ML
48 papers · 2 as a fellow
- MH
36 papers
- ET
33 papers · 1 as a fellow
- BC
27 papers
26 papers
- MM
23 papers
- RP
23 papers
Grants
- 2017–2027
Architecture and Trajectory of Acquired Resistance to Therapy in AML
National Cancer Institute · U54
PI · $12.5M · Oregon Health & Science University
- 1997–2027
National Cancer Institute · P30
Contact PI · $36.9M · Oregon Health & Science University
- 2022–2027
Proteogenomic Characterization of Early and Late Resistance Mechanisms in Acute Myeloid Leukemia
National Cancer Institute · U01
PI · $5.8M · Oregon Health & Science University
- 2018–2025
National Cancer Institute · R25
PI · $2.1M · Oregon Health & Science University
Clinical trials
- 2016–2020
Principal investigator · Completed · Phase 1
OHSU Knight Cancer Institute
- 2004–2027
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
- 2001–2011
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Study chair · Terminated · Phase 2
OHSU Knight Cancer Institute
- 2001–2011
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Study chair · Terminated · Phase 2
OHSU Knight Cancer Institute